- Home
- SNYR vs ZBIO Comparison
SNYR vs ZBIO Comparison
Compare SNYR & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNYR
- ZBIO
- Stock Information
- Founded
- SNYR 2010
- ZBIO 2019
- Country
- SNYR United States
- ZBIO United States
- Employees
- SNYR N/A
- ZBIO N/A
- Industry
- SNYR
- ZBIO
- Sector
- SNYR
- ZBIO
- Exchange
- SNYR NYSE
- ZBIO NYSE
- Market Cap
- SNYR 16.6M
- ZBIO 389.2M
- IPO Year
- SNYR N/A
- ZBIO 2024
- Fundamental
- Price
- SNYR $3.24
- ZBIO $9.54
- Analyst Decision
- SNYR Strong Buy
- ZBIO Strong Buy
- Analyst Count
- SNYR 1
- ZBIO 7
- Target Price
- SNYR $10.00
- ZBIO $32.29
- AVG Volume (30 Days)
- SNYR 109.7K
- ZBIO 223.0K
- Earning Date
- SNYR 08-24-2025
- ZBIO 08-16-2025
- Dividend Yield
- SNYR N/A
- ZBIO N/A
- EPS Growth
- SNYR N/A
- ZBIO N/A
- EPS
- SNYR 0.30
- ZBIO N/A
- Revenue
- SNYR $33,592,914.00
- ZBIO $15,000,000.00
- Revenue This Year
- SNYR $37.83
- ZBIO $206.00
- Revenue Next Year
- SNYR $18.39
- ZBIO $41.92
- P/E Ratio
- SNYR $10.69
- ZBIO N/A
- Revenue Growth
- SNYR N/A
- ZBIO N/A
- 52 Week Low
- SNYR $0.36
- ZBIO $5.83
- 52 Week High
- SNYR $10.00
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- SNYR N/A
- ZBIO N/A
- Support Level
- SNYR N/A
- ZBIO N/A
- Resistance Level
- SNYR N/A
- ZBIO N/A
- Average True Range (ATR)
- SNYR 0.00
- ZBIO 0.00
- MACD
- SNYR 0.00
- ZBIO 0.00
- Stochastic Oscillator
- SNYR 0.00
- ZBIO 0.00
About SNYR SYNERGY CHC CORP
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.